Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3400-3405

  Innocenti, F ^a   Stadler, W M ^a   Iyer, L ^a   Ramirez, J ^a   Vokes, E E ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; KIDNEY CANCER; LIVER METABOLISM; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II; CYCLIN-DEPENDENT KINASES; DIARRHEA; FEMALE; FLAVONOIDS; GLUCURONATES; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES;

EID: 0033812443     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Preclinical and clinical development of cyclin-dependent kinase modulators
2. Antitumor activity of flavone L86-8275
3. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy
4. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
5. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
6. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
7. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
8. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity
9. Cancer cell cycles
10. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
11. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
12. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
13. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
14. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
15. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
16. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells
17. Phase I clinical and pharmacokinetic trial of flavopiridol
18. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
19. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
20. In vitro glucuronidation of flavopiridol (NSC649890) (FLAVO) by human liver microsomes
21. A novel chemotherapeutic agent, flavopiridol, modulates intestinal epithelial chloride secretion
22. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer patients: A University of Chicago Phase II Consortium study
23. Drug glucuronidation in humans
24. Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum
25. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
26. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
27. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
28. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma
29. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
30. Flavonoids: Old and new aspects of a class of natural therapeutic drugs
31. Flavopiridol (NSC649890) pharmacokinetics suggest enterohepatic circulation
32. Absorption, metabolism and health effects of dietary flavonoids in man
33. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans
34. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
35. Determination of drug-metabolizing enzyme activity in vivo: Pharmacokinetic and statistical issues
36. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
37. Inherited variations in drug-metabolizing enzymes: Significance in clinical oncology
38. Pharmacogenetics and cancer chemotherapy
39. Clinical pharmacology of 5-fluorouracil
40. Paradoxical relationship between acetylator phenotype and amonafide toxicity
41. The clinical pharmacology of 6-mercaptopurine
42. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)
43. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene
44. Characterization and substrate specificity of UGT2B4 (E458): A UDP-glucuronosyltransferase encoded by a polymorphic gene
45. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
46. A Phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB)